<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:bef8762b-7935-441c-abc4-a2dc43a0414d,g:fd84582f-305c-4baa-8794-528d195fb06f,d:fb6d2ee08b5c4984b0baa85b1941c64d--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20201125</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF80L2ZyYWc6MzE1NWM5OTJlNGVlNDcxMzkzZjNiNzRhNTc1OGUyZmYvdGFibGU6M2QxMGFmM2M3OGYxNDVjM2FjOGExMGUxNzU0YWEyYTUvdGFibGVyYW5nZTozZDEwYWYzYzc4ZjE0NWMzYWM4YTEwZTE3NTRhYTJhNV8yLTEtMS0xLTA_a2ada3e1-9c57-458f-8b9f-b892e2ec330d">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF80L2ZyYWc6MzE1NWM5OTJlNGVlNDcxMzkzZjNiNzRhNTc1OGUyZmYvdGFibGU6M2QxMGFmM2M3OGYxNDVjM2FjOGExMGUxNzU0YWEyYTUvdGFibGVyYW5nZTozZDEwYWYzYzc4ZjE0NWMzYWM4YTEwZTE3NTRhYTJhNV8zLTEtMS0xLTA_ca6113b8-9952-40ab-b16f-1f457dde932a">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20201125.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-16</xbrli:startDate><xbrli:endDate>2020-06-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifb6d2ee08b5c4984b0baa85b1941c64d_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ2_044aaee5-a154-48d9-9cd7-1da13d9681c3">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8yMzI_ffd96351-51ff-4a68-ab34-00fe7185c27e">November 25, 2020</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQy_d4bf748d-291a-436e-b6e8-c2d4fa3fc348">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:18.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl8wLTAtMS0xLTA_e171eaa0-02e1-49c0-8992-8922044e0945">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl8wLTMtMS0xLTA_3e536cb7-24eb-45f9-89ac-12f4ff82668c">001-36112</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl8wLTUtMS0xLTA_a442fb1e-2ed7-45e0-99e2-c79d8528566a">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl8zLTAtMS0xLTA_a0d8dfa7-38c3-4248-a5d3-bdada6f431dc">9704 Medical Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl80LTAtMS0xLTA_48f5f846-300c-4b94-ab35-d51e6bdaf751">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl80LTEtMS0xLTA_d40ab896-528d-460d-bc1c-7e3bf22a0b94">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6NmVhMThjYzM1ZWNiNDZlOThmZTcwNTQ5NTA1YzQ2ZGIvdGFibGVyYW5nZTo2ZWExOGNjMzVlY2I0NmU5OGZlNzA1NDk1MDVjNDZkYl80LTMtMS0xLTA_e7dcfa55-8a79-4a8e-b7da-fbb95ce16034">20850</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQz_68be31d0-5950-482c-abac-53c65b1981b1">301</ix:nonNumeric>) <ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ3_48ba5f3c-e2d6-49ac-a7f9-9a04b9af6896">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6OTBmMTQyZTI3MWM2NGI1M2E4NzgyZWM3NjlkNGIwNTAvdGFibGVyYW5nZTo5MGYxNDJlMjcxYzY0YjUzYTg3ODJlYzc2OWQ0YjA1MF8xLTAtMS0xLTA_05e41695-b926-4427-b34c-be93450eb6c8">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6OTBmMTQyZTI3MWM2NGI1M2E4NzgyZWM3NjlkNGIwNTAvdGFibGVyYW5nZTo5MGYxNDJlMjcxYzY0YjUzYTg3ODJlYzc2OWQ0YjA1MF8xLTEtMS0xLTA_b0e94a0c-dfd6-4084-84f7-ea5b50efbeb3">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGFibGU6OTBmMTQyZTI3MWM2NGI1M2E4NzgyZWM3NjlkNGIwNTAvdGFibGVyYW5nZTo5MGYxNDJlMjcxYzY0YjUzYTg3ODJlYzc2OWQ0YjA1MF8xLTItMS0xLTA_0399aa45-fc83-4fdc-b8ce-f548180e668f">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ4_85d2aad1-c697-4d02-8f4f-7e83af7bd052">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ0_331c161f-c6d1-4379-8a8e-930f2e0592b2">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ5_e24fbad5-f61f-47b9-ac0e-80f8bbcb5b28">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjQ1_1e069bea-a441-4f1c-b57b-7daa8c1dcd08">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="i97ea587d11ad4d338bf6f195426d057b_D20200616-20200616" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmZiNmQyZWUwOGI1YzQ5ODRiMGJhYTg1YjE5NDFjNjRkL3NlYzpmYjZkMmVlMDhiNWM0OTg0YjBiYWE4NWIxOTQxYzY0ZF8xL2ZyYWc6MzkyYTA0MzU3MmZjNDYzZWI4YTc4M2EyYjRkMjRmZjgvdGV4dHJlZ2lvbjozOTJhMDQzNTcyZmM0NjNlYjhhNzgzYTJiNGQyNGZmOF8xNjUw_5e13164d-5bfd-4b79-9dcc-ae583a5550d6">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ifb6d2ee08b5c4984b0baa85b1941c64d_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entry into a Material Definitive Agreement</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;25, 2020,  </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics entered into a Product Commercialization A</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">greement, or the Agreement,</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVERSANA Life Sciences Services, LLC, or Eversana, for the potential commercialization of MacroGenics&#8217; investigational product, margetuximab. Pursuant to the </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, Eversana will provide commercialization services to MacroGenics, as well as </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the provision of marketing, sales, logistics and other services, </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if margetuximab is approved by the United States Food &amp; Drug Administration (FDA)</span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, MacroGenics will maintain ownership of, and will have legal, regulatory, and manufacturing responsibilities for, margetuximab.</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eversana will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services. MacroGenics will book sales for margetuximab.</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Agreement, Eversana will conduct the commercialization activities according to an agreed upon plan and budget.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to a potential FDA approval of margetuximab, MacroGenics will pay Eversana on a fee-for-service basis for its services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter, the parties will share costs equally and Eversana will earn future revenue share payments which shall be capped at 125% of Eversana&#8217;s cumulative service fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the cap is reached, MacroGenics will compensate Eversana for its services on a fee-for-service basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Agreement is from the date of execution until five years from the date, if any, of an FDA approval of margetuximab.</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Agreement may be earlier terminated (i) by Eversana for pre-defined product performance reasons, or (ii) by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics for convenience by providing notice no earlier than 24 months post FDA approval of margetuximab, or for a change of product control, including an exclusive licensing arrangement for margetuximab with a third-party.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete Product Commercialization Agreement, which will be filed in redacted form as an exhibit to the Company&#8217;s Annual Report on Form 10-K for the year ending December 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, MacroGenics issued a press release announcing that MacroGenics entered into the Agreement with Eversana.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. </span></div><div><span><br/></span></div><div id="ifb6d2ee08b5c4984b0baa85b1941c64d_47"></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:16.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Statements and Exhibits</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(d) Exhibits.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="eversanapressrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="eversanapressrelease.htm">Press Release dated </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="eversanapressrelease.htm">November </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="eversanapressrelease.htm">30, 2020</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="ifb6d2ee08b5c4984b0baa85b1941c64d_10"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.032%"><tr><td style="width:1.0%"></td><td style="width:44.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  November 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "mgnx-20201125.htm", "description": "8-K", "secsgml_size_bytes": 39792}]
{"company-data": {"conformed-name": "MACROGENICS INC", "cik": "0001125345", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36112", "film-number": "201358472"}, "business-address": {"street1": "9704 MEDICAL CENTER DRIVE", "city": "Rockville", "state": "MD", "zip": "20850", "phone": "301-251-5172"}, "mail-address": {"street1": "9704 MEDICAL CENTER DRIVE", "city": "ROCKVILLE", "state": "MD", "zip": "20850"}}
mgnx-20201125
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 25, 2020
MACROGENICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-36112
06-1591613
(State or Other Jurisdiction of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
9704 Medical Center Drive
Rockville,
Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(
301
)
251-5172
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
MGNX
Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
Item 1.01
Entry into a Material Definitive Agreement
On November 25, 2020,
MacroGenics entered into a Product Commercialization A
greement, or the Agreement,
with
EVERSANA Life Sciences Services, LLC, or Eversana, for the potential commercialization of MacroGenics' investigational product, margetuximab. Pursuant to the
Agreement, Eversana will provide commercialization services to MacroGenics, as well as
the provision of marketing, sales, logistics and other services,
if margetuximab is approved by the United States Food & Drug Administration (FDA)
.
Under the terms of the Agreement, MacroGenics will maintain ownership of, and will have legal, regulatory, and manufacturing responsibilities for, margetuximab.
Eversana will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services. MacroGenics will book sales for margetuximab.
Pursuant to the Agreement, Eversana will conduct the commercialization activities according to an agreed upon plan and budget.
Prior to a potential FDA approval of margetuximab, MacroGenics will pay Eversana on a fee-for-service basis for its services.
Thereafter, the parties will share costs equally and Eversana will earn future revenue share payments which shall be capped at 125% of Eversana's cumulative service fees.
After the cap is reached, MacroGenics will compensate Eversana for its services on a fee-for-service basis.
The term of the Agreement is from the date of execution until five years from the date, if any, of an FDA approval of margetuximab.
The Agreement may be earlier terminated (i) by Eversana for pre-defined product performance reasons, or (ii) by
MacroGenics for convenience by providing notice no earlier than 24 months post FDA approval of margetuximab, or for a change of product control, including an exclusive licensing arrangement for margetuximab with a third-party.
The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete Product Commercialization Agreement, which will be filed in redacted form as an exhibit to the Company's Annual Report on Form 10-K for the year ending December 31, 2020.
On November 30, 2020, MacroGenics issued a press release announcing that MacroGenics entered into the Agreement with Eversana.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits.
Exhibit Number
Description of Exhibit
99.1
Press Release dated
November
30, 2020
104
Cover Page Interactive Data (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MACROGENICS, INC.
Date:  November 30, 2020
By:
Name:
Title:
/s/ Jeffrey Peters
Jeffrey Peters
Vice President and General Counsel